Jilin Province Huinan Changlong Bio-pharm (8049.HK) released earnings for its full year that Increased, from last year
The company's earnings came in at RMB198.88 million, or RMB0.355 per share. This compares with RMB184.25 million, or RMB0.3289 per share, last year.
The company's revenue for the period rose 2.4% to RMB901.87 million from RMB881.16 million last year.
Jilin Province Huinan Changlong Bio-pharm earnings at a glance (GAAP) :
-Earnings: RMB198.88 Mln. vs. RMB184.25 Mln. last year.-EPS: RMB0.355 vs. RMB0.3289 last year.-Revenue: RMB901.87 Mln vs. RMB881.16 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.